Amarin Corp Plcuk (AMRN) Income towards Parent Company (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Income towards Parent Company of -$10.5 million for Q1 2026, up 33.03% YoY from -$7.9 million in Q1 2025, and down 758.82% sequentially from -$1.2 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Income towards Parent Company (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Income towards Parent Company across 17 years of filings, most recently posting -$10.5 million for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 33.03% year-over-year to -$10.5 million; the TTM figure through Mar 2026 stood at -$33.6 million (down 109.94% YoY), while the FY2025 annual figure was -$38.8 million, down 277.89% from the prior year.
- Income towards Parent Company fell to -$10.5 million in Q1 2026, from -$1.2 million in the prior quarter.
- Over the last five years, Income towards Parent Company for AMRN reached as high as $110.0 million in Q4 2022 and fell as low as -$70.0 million in Q2 2022.
- The 5-year median for Income towards Parent Company is -$10.5 million (2026), against an average of -$6.8 million.
- The widest YoY moves for Income towards Parent Company: up 648.53% in 2022, down 1841.14% in 2022.
- A 5-year view of Income towards Parent Company shows it stood at $110.0 million in 2022, then tumbled by 105.25% to -$5.8 million in 2023, then soared by 503.01% to $23.3 million in 2024, then plunged by 105.25% to -$1.2 million in 2025, then tumbled by 758.82% to -$10.5 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$10.5 million, -$1.2 million, and -$7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.51 Mn |
| Dec 31, 2025 | -1.22 Mn |
| Sep 30, 2025 | -7.74 Mn |
| Jun 30, 2025 | -14.14 Mn |
| Mar 31, 2025 | -15.70 Mn |
| Dec 31, 2024 | 23.30 Mn |
| Sep 30, 2024 | -25.13 Mn |
| Jun 30, 2024 | 1.52 Mn |
| Mar 31, 2024 | -9.95 Mn |
| Dec 31, 2023 | -5.78 Mn |
| Sep 30, 2023 | -19.31 Mn |
| Jun 30, 2023 | -17.56 Mn |
| Mar 31, 2023 | -16.46 Mn |
| Dec 31, 2022 | 110.02 Mn |
| Sep 30, 2022 | -5.14 Mn |
| Jun 30, 2022 | -69.96 Mn |
| Mar 31, 2022 | -31.56 Mn |
| Dec 31, 2021 | 14.70 Mn |
| Sep 30, 2021 | -13.15 Mn |
| Jun 30, 2021 | 7.81 Mn |